IRIS
TOMELLERI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.366
AS - Asia 1.628
NA - Nord America 1.417
SA - Sud America 280
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 5.728
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.328
RU - Federazione Russa 1.218
SG - Singapore 551
CN - Cina 515
IT - Italia 304
RO - Romania 265
BR - Brasile 234
HK - Hong Kong 204
SE - Svezia 170
VN - Vietnam 134
DE - Germania 118
FR - Francia 81
BD - Bangladesh 63
GB - Regno Unito 62
CA - Canada 61
FI - Finlandia 39
IN - India 31
JP - Giappone 25
PH - Filippine 25
AR - Argentina 22
PL - Polonia 22
MX - Messico 20
NL - Olanda 20
ES - Italia 18
AT - Austria 14
TR - Turchia 11
ZA - Sudafrica 11
ID - Indonesia 9
LT - Lituania 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
EG - Egitto 7
CO - Colombia 6
IQ - Iraq 6
UA - Ucraina 6
EC - Ecuador 5
IE - Irlanda 5
MK - Macedonia 5
NP - Nepal 5
UZ - Uzbekistan 5
VE - Venezuela 5
IR - Iran 4
SA - Arabia Saudita 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
KE - Kenya 3
KR - Corea 3
KZ - Kazakistan 3
MA - Marocco 3
PY - Paraguay 3
AL - Albania 2
BE - Belgio 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
PE - Perù 2
PK - Pakistan 2
TH - Thailandia 2
UY - Uruguay 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
GE - Georgia 1
GT - Guatemala 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LV - Lettonia 1
MN - Mongolia 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SN - Senegal 1
TG - Togo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 5.728
Salva come PNG Salva come JPEG
Città #
Singapore 278
Moscow 241
Ashburn 212
Dallas 205
Hong Kong 197
San Jose 161
Shanghai 116
New York 75
Beijing 69
Milan 69
Hefei 63
Munich 59
Lauterbourg 55
Ho Chi Minh City 52
Los Angeles 51
Boardman 38
São Paulo 36
Lawrence 31
Princeton 31
Hanoi 23
Rome 22
Orem 21
Helsinki 20
Nuremberg 19
Warsaw 19
Montreal 18
Santa Clara 18
Tokyo 17
Atlanta 16
Chicago 14
Denver 13
Turku 13
Cesano Boscone 12
Council Bluffs 12
London 12
Brooklyn 11
Phoenix 11
Toronto 11
Chennai 10
Guangzhou 10
Johannesburg 10
Poplar 10
Stockholm 10
Makati City 9
Naples 9
Pune 9
Ankara 8
Manchester 8
Pietra Ligure 8
Rio de Janeiro 8
Shenzhen 8
Mexico City 7
Bari 6
City of London 6
Falkenstein 6
Frankfurt am Main 6
Haiphong 6
Lappeenranta 6
Amsterdam 5
Ancona 5
Boston 5
Buffalo 5
Dublin 5
Florence 5
Genoa 5
Houston 5
Querétaro 5
San Francisco 5
Tashkent 5
Verona 5
Vittoria 5
Wolfhagen 5
Barnet 4
Brasília 4
Cairo 4
Da Nang 4
Foshan 4
Goito 4
Jiaxing 4
Pisa 4
Pristina 4
Quezon City 4
Seattle 4
Skopje 4
Sydney 4
Taizhou 4
The Dalles 4
Trento 4
Valencia 4
Vancouver 4
Vienna 4
Zhengzhou 4
Alessandria 3
Annapolis 3
Baie-D'Urfé 3
Bauru 3
Belo Horizonte 3
Bismarck 3
Brescia 3
Cabanatuan City 3
Totale 2.675
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 388
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 177
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 171
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 167
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 143
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM) 136
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 131
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 125
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 123
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 119
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 116
Case report: Cytopenias in VEXAS syndrome - a WHO 2022 based approach in a single-center cohort 113
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 113
Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort 110
Drug retention rates of biological agents in adult onset Still's disease 107
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 106
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 106
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 104
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 103
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 100
Giant cell arteritis: Update on clinical manifestations, diagnosis, and management 100
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 100
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 99
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 99
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 97
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 96
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 94
Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India 93
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 92
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 92
VEXAS associated acute disseminated Encephalo-Myelitis (ADEM)-like syndrome: A case report and review of the literature 90
Clinically isolated aortitis successfully treated with methotrexate monotherapy 90
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients 89
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 89
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 88
An enlightening scan 86
LONG-TERM PATHOPHYSIOLOGIC AND PROGNOSTIC EVALUATION OF DIFFERENT DISEASE SUBSETS IN GIANT CELL ARTERITIS 84
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 74
Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement 73
HETEROGENEITY OF CYTOPENIAS IN VEXAS SYNDROME: A SINGLE CENTRE EXPERIENCE 69
The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort 69
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 69
Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study 65
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 64
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease 61
Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: A monocentric survey 60
Response to: 'Correspondence on Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: A monocentric survey' by Comarmond et al 59
Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement 59
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 57
Efficacy of interleukin-1 blockade with anakinra in the management of post-COVID-19 steroid-dependent multisystem inflammatory syndrome: a case report 54
Potential acceptance of COVID-19 vaccine in rheumatological patients: A monocentric comparative survey 54
Failure of first anti-TNF agent in Takayasu’s arteritis: To switch or to swap? 53
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 53
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 52
Retention rates of different Janus kinase inhibitors in rheumatoid arthritis: experience from a large monocentric cohort 51
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance 49
Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis 49
One year later: The case of tocilizumab in COVID-19 47
Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients 47
Multimodal chorioretinal imaging in erdheim-chester disease 47
Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease 45
Myocardial infarction in giant cell arteritis: It is all a matter of balance 45
The target on B cells in Systemic Sclerosis: a “midsummer dream” to extinguish inflammation and prevent early disease progression to fibrosis 44
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply 41
Spontaneous coronary-artery dissection 37
Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir 6
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 1
Safety and effectiveness of the combination of 5-azacitidine and ruxolitinib in VEXAS syndrome: A single-centre experience 1
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 1
Totale 5.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.164
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 0 2
2021/202264 0 0 23 17 2 4 6 2 4 3 0 3
2022/2023305 75 58 15 3 8 36 29 38 19 10 9 5
2023/2024403 11 30 52 36 34 59 33 44 3 7 15 79
2024/20251.367 100 29 44 39 68 89 408 118 161 103 91 117
2025/20263.717 256 229 258 483 295 106 292 316 1.041 209 116 116
Totale 5.892